3
Clinical Trials associated with Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical )A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes
The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.
/ Unknown statusPhase 1/2IIT Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
/ Unknown statusPhase 1/2IIT Multi-center Phase I/II Clinical Trial of Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.
100 Clinical Results associated with Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical )
100 Translational Medicine associated with Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical )
100 Patents (Medical) associated with Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical )
100 Deals associated with Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical )